ERBB2 and breast carcinoma: In breast cancer, for example, the enumeration and characterization of CTCs for ER, PR, HER2, PI3K, BRCA, etc. is supposed to properly identify not only the timing of treatment changes, but, more importantly, to select the most appropriate treatment type.